Cargando…

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV

Hepatitis B- and C-virus (HBV and HCV) infections contribute to hepatocellular carcinoma (HCC) development through several different mechanisms. In addition to a diverse molecular background, HCC subtypes also show differences in their metabolic profiles, suggesting that prevention and treatment mig...

Descripción completa

Detalles Bibliográficos
Autores principales: De Matteis, Serena, Ghetti, Martina, Gramantieri, Laura, Marisi, Giorgia, Casadei-Gardini, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335550/
https://www.ncbi.nlm.nih.gov/pubmed/34366674
http://dx.doi.org/10.2147/OTT.S312748
Descripción
Sumario:Hepatitis B- and C-virus (HBV and HCV) infections contribute to hepatocellular carcinoma (HCC) development through several different mechanisms. In addition to a diverse molecular background, HCC subtypes also show differences in their metabolic profiles, suggesting that prevention and treatment might require the integration of multiple different approaches. We here analyzed the response of two HCC cell lines representative of different virus-related etiology, namely Hep3B (HBV+) and HUH7 (permissive to HCV replication) to sorafenib treatment. Our findings suggest that virus-related specificities influence treatment response in HCC, along with molecular, metabolic and microenvironmental factors. These differences have to be taken into account in the design of future clinical trial aimed to improve HCC patients’ outcome.